Cantor Fitzgerald Estimates Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Cabaletta Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($2.19) per share for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

A number of other analysts also recently issued reports on CABA. UBS Group began coverage on shares of Cabaletta Bio in a report on Thursday, October 10th. They set a “buy” rating and a $10.00 price target on the stock. Evercore ISI cut shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their target price for the stock from $15.00 to $6.00 in a report on Friday, December 20th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. Wells Fargo & Company downgraded Cabaletta Bio from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $12.00 to $6.00 in a research note on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Cabaletta Bio has an average rating of “Buy” and an average price target of $24.38.

Cabaletta Bio Stock Performance

NASDAQ CABA opened at $2.59 on Thursday. Cabaletta Bio has a one year low of $1.76 and a one year high of $26.35. The stock has a 50-day moving average of $2.65 and a 200 day moving average of $4.30. The company has a market capitalization of $126.60 million, a price-to-earnings ratio of -1.20 and a beta of 2.46.

Institutional Trading of Cabaletta Bio

Several hedge funds have recently bought and sold shares of CABA. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Cabaletta Bio during the 3rd quarter valued at about $32,000. Point72 DIFC Ltd bought a new stake in Cabaletta Bio during the 3rd quarter worth approximately $33,000. Avanza Fonder AB purchased a new position in Cabaletta Bio during the fourth quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Cabaletta Bio by 65.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after purchasing an additional 3,724 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Cabaletta Bio in the third quarter worth $67,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.